- Policy
- Co-pay rate of advanced hospitals for cold patients to 80%
- by Lee. Chang jin Apr 1, 2020 06:21am
- As soon as the plan to reorganize the medical delivery system, which has shown a lull in the event of COVID-19, is expected to be presented to the Health Insurance Policy Deliberative Committee during this month. In particular, it is noteworthy that a plan to increase the outpatient co-payment rate of minor patients, such as simple colds usin
- Policy
- Bioequivalence reevaluation may hinder drug license renewal
- by Lee, Tak-Sun Apr 1, 2020 06:21am
- Korean pharmaceutical industry is voicing their concerns about the Ministry of Food and Drug Safety’s (MFDS) plan to revive bioequivalence reevaluation and to toughen the item license renewal review procedure. Arguing the government’s redundant review could harm them, the industry claims the ministry should set down more consistent re
- Policy
- Coverage on COVID-19 treatments to last a year
- by Lee, Hye-Kyung Apr 1, 2020 06:20am
- Despite the expedited review, the health insurance reimbursement on the off-label drug would be reassessed a year after due to the COVID-19 outbreak. Korea’s Health Insurance Review and Assessment Service (HIRA) disseminated a press release on Mar. 30 and stated, “Taking in account the latest medical case studies and expert recommendation,
- Policy
- Renewal of Marketing Approval for drugs, will be reinforced
- by Lee, Tak-Sun Mar 31, 2020 06:29am
- Renewal System of Marketing Approval for Drugs ongoing since 2018 will be further reinforced. The system which gives a 5 year validity for each category respectively, renews allowance after reviewing safety and effectiveness. However, it is criticized that the screening does not properly evaluate the safety and effectiveness of pharmaceut
- Policy
- Asthma inhaler Alvesco, clinical trial for COVID-19 patients
- by Lee, Tak-Sun Mar 31, 2020 06:28am
- Alvesco inhalers (Ciclesonide, AstraZeneca), which are being used as an asthma treatment, conduct clinical trials on COVID-19 patients. Institut Pasteur Korea (Director Wang-Sik Ryu) announced on the 29th that IIT for 'Alvesco' was approved based on the research results. IIT are led by Professor Woo-Joo Kim, Infectious Medicine of Korea
- Policy
- 5 out of 11 COVID-19 trials approved to speed up development
- by Lee, Tak-Sun Mar 31, 2020 06:28am
- Apparently, total 11 clinical trials in patients with COVID-19 have applied for the Korean health authority’s approval and five of them were cleared. The Korean government says pharmaceutical companies have sufficient stock of Kaletra and hydroxychloroquine used to treat COVID-19. On Mar. 27, Ministry of Food and Drug Safety (MFDS, Mi
- Policy
- Champix salt-modified drugs ready for launch in July
- by Lee, Tak-Sun Mar 31, 2020 06:28am
- The substance patent expiration on smoking cessation drug Champix is approaching in coming July, and more drugs with modified salt base are applying for market approval. Although the Korean court has ruled against salt-modified drugs launching before Champix’ patent expiration, new drugs are hectic preparing for their release immediately fo
- Policy
- President Moon, COVID-19 treatment should be cooperated
- by Lee, Jeong-Hwan Mar 31, 2020 06:28am
- President Moon Jae-in raised the need for international solidarity and policy coordination to develop new treatments and vaccines for new coronavirus infections (COVID-19). It was also said to maintain the essential flow of economic exchange between countries to minimize the negative impact COVID-19 has on the world economy. It was held
- Policy
- Strengthen the standards of international conference support
- by Kim, Jung-Ju Mar 30, 2020 09:42am
- A draft of improved standards for supporting academic conferences, which have been partially exploited as a link between medical/medical device companies and medical rebates, has been prepared. In the case of the international conferences, the number of participants participating in the evaluation criteria has been strengthened three time
- Policy
- How will be negotiated generic drug prices?
- by Lee, Hye-Kyung Mar 30, 2020 06:18am
- The details of the amendments to various systems that change the framework for drug coverage have been unveiled at once. The MOHW and the HIRA announced on the 23rd, 'Partial Amendments to the Rules for Pharmaceutical Reimbursement Listing Standard and Methods (Draft)', 'Criteria for Decision or Adjustment on Drugs', 'Partially revised detail
